MetLife Investment Advisors LLC Decreases Holdings in Innoviva Inc (INVA)
MetLife Investment Advisors LLC trimmed its position in shares of Innoviva Inc (NASDAQ:INVA) by 33.6% during the fourth quarter, HoldingsChannel reports. The firm owned 33,334 shares of the biotechnology company’s stock after selling 16,858 shares during the quarter. MetLife Investment Advisors LLC’s holdings in Innoviva were worth $582,000 at the end of the most recent quarter.
A number of other large investors have also recently added to or reduced their stakes in INVA. Oregon Public Employees Retirement Fund purchased a new stake in shares of Innoviva during the fourth quarter worth $26,000. Financial Gravity Companies Inc. purchased a new stake in shares of Innoviva during the fourth quarter worth $40,000. Fort L.P. purchased a new stake in shares of Innoviva during the fourth quarter worth $90,000. Quantamental Technologies LLC purchased a new stake in shares of Innoviva during the fourth quarter worth $172,000. Finally, Magnus Financial Group LLC purchased a new stake in shares of Innoviva during the fourth quarter worth $199,000. Institutional investors own 79.06% of the company’s stock.
Several research firms recently commented on INVA. Zacks Investment Research raised Innoviva from a “hold” rating to a “buy” rating and set a $17.00 target price on the stock in a report on Friday, February 8th. BidaskClub lowered Innoviva from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 2nd. Finally, ValuEngine raised Innoviva from a “sell” rating to a “hold” rating in a report on Monday, February 25th. One analyst has rated the stock with a sell rating, three have given a hold rating and one has issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $16.50.
NASDAQ:INVA opened at $14.14 on Wednesday. The firm has a market capitalization of $1.45 billion, a P/E ratio of 4.01 and a beta of 1.86. The company has a debt-to-equity ratio of 2.41, a quick ratio of 34.92 and a current ratio of 34.92. Innoviva Inc has a 12 month low of $13.26 and a 12 month high of $20.54.
Innoviva (NASDAQ:INVA) last posted its earnings results on Wednesday, February 6th. The biotechnology company reported $2.34 EPS for the quarter. The firm had revenue of $79.86 million for the quarter. Innoviva had a negative return on equity of 508.18% and a net margin of 151.36%. Analysts predict that Innoviva Inc will post 1.43 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This report was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The original version of this report can be read at https://www.watchlistnews.com/metlife-investment-advisors-llc-decreases-holdings-in-innoviva-inc-inva/2953003.html.
Innoviva Company Profile
Innoviva, Inc engages in the development and commercialization of pharmaceuticals. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a long-acting beta2 agonist (LABA), vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate (FF); ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA and LABA.
Further Reading: How is a buy-side analyst different from a sell-side analyst?
Want to see what other hedge funds are holding INVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Innoviva Inc (NASDAQ:INVA).
Receive News & Ratings for Innoviva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva and related companies with MarketBeat.com's FREE daily email newsletter.